HKPOLYU

October 21, 2023

HKPOLYU # An innovative approach to construct a bispecific antibody to combat the Osimertinib resistance in NSCLC # Our project addresses the critical issue of Osimertinib resistance in non-small cell lung carcinoma (NSCLC). NSCLC accounts for 85% of all lung cancer cases and the average five-year survival rate is only 28%. Apart from common treatments such as surgery, chemotherapy, and checkpoint inhibitors, Osimertinib, as the first-line targeted therapy for NSCLC patients with an EGFR mutation, can develop acquired drug resistance, thus affecting its long-term efficacy. ...